SG144141A1 - Semi-solid systems containing azetidine derivatives - Google Patents

Semi-solid systems containing azetidine derivatives

Info

Publication number
SG144141A1
SG144141A1 SG200804303-6A SG2008043036A SG144141A1 SG 144141 A1 SG144141 A1 SG 144141A1 SG 2008043036 A SG2008043036 A SG 2008043036A SG 144141 A1 SG144141 A1 SG 144141A1
Authority
SG
Singapore
Prior art keywords
semi
systems containing
azetidine derivatives
solid systems
containing azetidine
Prior art date
Application number
SG200804303-6A
Other languages
English (en)
Inventor
Maria-Teresa Peracchia
Sophie Cote
Valerie Bobineau
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of SG144141A1 publication Critical patent/SG144141A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200804303-6A 2003-07-18 2004-07-08 Semi-solid systems containing azetidine derivatives SG144141A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03291796A EP1498122A1 (en) 2003-07-18 2003-07-18 Semi-solid systems containing azetidine derivatives

Publications (1)

Publication Number Publication Date
SG144141A1 true SG144141A1 (en) 2008-07-29

Family

ID=33462259

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200804303-6A SG144141A1 (en) 2003-07-18 2004-07-08 Semi-solid systems containing azetidine derivatives

Country Status (30)

Country Link
US (2) US20050026898A1 (pt)
EP (2) EP1498122A1 (pt)
JP (1) JP2009513560A (pt)
KR (1) KR20060040691A (pt)
CN (1) CN1822831A (pt)
AR (1) AR045997A1 (pt)
AU (1) AU2004262498B2 (pt)
BR (1) BRPI0412737A (pt)
CA (1) CA2532669A1 (pt)
CR (1) CR8179A (pt)
EC (1) ECSP066292A (pt)
GT (1) GT200400135A (pt)
HR (1) HRP20060022A2 (pt)
IL (1) IL173111A0 (pt)
MA (1) MA27922A1 (pt)
MX (1) MXPA06000483A (pt)
MY (1) MY142077A (pt)
NO (1) NO20060509L (pt)
OA (1) OA13191A (pt)
PA (1) PA8606701A1 (pt)
PE (1) PE20050287A1 (pt)
RS (1) RS20060016A (pt)
RU (1) RU2343915C2 (pt)
SG (1) SG144141A1 (pt)
TN (1) TNSN06013A1 (pt)
TW (1) TW200522945A (pt)
UA (1) UA80633C2 (pt)
UY (1) UY28421A1 (pt)
WO (1) WO2005013973A1 (pt)
ZA (1) ZA200600490B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1817012A2 (en) * 2004-11-24 2007-08-15 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
FR2923719B1 (fr) * 2007-11-15 2009-11-20 Sanofi Aventis Compositions pharmaceutiques a base de derives d'azetidine
CN101926757B (zh) 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
EP2637655B1 (en) * 2010-11-08 2019-01-09 Cadila Pharmaceuticals Ltd. Pharmaceutical composition of taxoids
CN105848643A (zh) * 2013-12-23 2016-08-10 强生消费者公司 消旋卡多曲组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996036316A1 (en) * 1995-05-19 1996-11-21 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs
WO2000003753A2 (en) * 1998-07-14 2000-01-27 Em Industries, Inc. Microdisperse drug delivery systems
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
FR2829027A1 (fr) * 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
FR2833842B1 (fr) * 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
EP1498123A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Emulsifying systems containing azetidine derivatives

Also Published As

Publication number Publication date
TNSN06013A1 (en) 2007-10-03
AR045997A1 (es) 2005-11-23
UA80633C2 (en) 2007-10-10
AU2004262498A1 (en) 2005-02-17
GT200400135A (es) 2005-08-25
IL173111A0 (en) 2006-06-11
ECSP066292A (es) 2006-10-25
CN1822831A (zh) 2006-08-23
UY28421A1 (es) 2005-02-28
RU2343915C2 (ru) 2009-01-20
RU2006105011A (ru) 2006-06-10
EP1648442A1 (en) 2006-04-26
BRPI0412737A (pt) 2006-09-26
HRP20060022A2 (en) 2006-02-28
AU2004262498A2 (en) 2005-02-17
RS20060016A (en) 2008-06-05
US20050026898A1 (en) 2005-02-03
JP2009513560A (ja) 2009-04-02
OA13191A (en) 2006-12-13
WO2005013973A1 (en) 2005-02-17
MA27922A1 (fr) 2006-06-01
CR8179A (es) 2006-09-22
NO20060509L (no) 2006-01-31
AU2004262498B2 (en) 2009-01-22
US20080293686A1 (en) 2008-11-27
TW200522945A (en) 2005-07-16
MXPA06000483A (es) 2006-04-05
ZA200600490B (en) 2007-05-30
KR20060040691A (ko) 2006-05-10
CA2532669A1 (en) 2005-02-17
PE20050287A1 (es) 2005-06-13
MY142077A (en) 2010-08-30
EP1498122A1 (en) 2005-01-19
PA8606701A1 (es) 2005-02-04

Similar Documents

Publication Publication Date Title
HK1076605A1 (en) Formulations
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
NZ527867A (en) Oral pharmaceutical composition of cefpodoxime proxetil
IL165790A0 (en) Cationically substituted diphenyl azetidinones method for their production medicaments containing said compounds and use thereof
MXPA05008960A (es) Oxazolidinonas de indolona antibacteriales, intermedios para su preparacion y composiciones farmaceuticas que las contienen.
TNSN06013A1 (en) Semi-solid systems containing azetidine derivatives
MXPA06000636A (es) Formulaciones semi-solidas para la administracion oral de taxoides.
MY139106A (en) Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
UA86393C2 (ru) Производные фениламино-1н-имидазола и фармацевтическая композиция, которая их содержит